Amani Fawzi, MD
Ophthalmology · Chicago, ILNPI 1558416313
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. F. Hoffmann-la Roche AG accounts for 64.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $25,469 and has fallen 73.5% since, to $6,746 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $1840.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$38K
- Regeneron$12K
- Genentech, Inc.$6K
- Boehringer Ingelheim International GmbH$2K
- Chugai Pharmaceutical Co., Ltd.$725
- Genentech USA, Inc.$76
- plus $30 from 1 others
Across 55 payments — averaging $14,848 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$612K
- Boehringer Ingelheim International GmbH$69K
- Genentech, Inc.$68K
- Hoffmann-la Roche Limited$32K
- Astellas Pharma Global Development$25K
- F. Hoffmann-la Roche AG$11K
What the payments were for
- Consulting fees$33,92558%
- Speaking & faculty fees$15,59426%
- Travel & lodging$8,63615%
- Food & beverage$7271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 22 | $37,904 |
| Regeneron | 2 | $11,922 |
| Genentech, Inc. | 2 | $6,000 |
| Boehringer Ingelheim International GmbH | 3 | $2,225 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $725 |
| Genentech USA, Inc. | 1 | $76 |
| Janssen Research & Development, LLC | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$25,393
- EYLEA$11,880
- VABYSMO$3,580
- Lucentis$2,420
How this compares
$58,881 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 30 | $898 |
| Brimonidine Tartrate | 15 | $70 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Dilraj GrewalChicago$188K
- Ahmad ArefChicago$179K
- Robert SchroederChicago$153K
- Jennifer LimChicago$150K
- Surendra BastiChicago$126K
- Allen PuttermanChicago$94K
- Maria CortinaChicago$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.